Latest Headlines

Latest Headlines

India's Cipla gets U.S. beachhead with $550M deal for 2 generics operations

India's Cipla has lagged behind its compatriots in challenging U.S. drugmakers on their own turf, currently getting less than 10% of its revenues from the lucrative U.S. market. The company is making moves to change that equation, announcing a small deal on Friday to buy two U.S. focused generics companies.

India's Cipla swoops down on two U.S. firms in $550M worth of deals

Indian generics maker Cipla has agreed to buy two U.S.-based companies, InvaGen Pharmaceuticals and Exelan Pharmaceuticals, in a total transaction valued at $550 million, making something of an unexpected play from its emerging market expansion focus.

GSK sinks Advair prices to fend off Cipla copycat in India

GlaxoSmithKline isn't just going to sit back and let Cipla's generic stomp all over asthma blockbuster Advair--known as Seretide outside the U.S.--in India. It's turning to a strategy it's used elsewhere to help its aging med compete, and that's price-cutting.

Pharma in India shakes up executive ranks at Ranbaxy, Cipla, others

A slew of senior executives at the Ranbaxy unit of India's Sun Pharmaceutical and Cipla are likely polishing up their Linkedin profiles and calling head hunters as something of a cull sweeps through management ranks at those companies and wider, highlighting deep changes in the industry.

Emerging markets, Advair generic the trick as India's Cipla eyes growth

Acquisitions that help Cipla grow in emerging markets are on the cards as the Indian drugmaker looks to expand into new geographies, Chief Executive Subhanu Saxena told the Reuters news agency in an interview this week.

Cipla, Lupin in UCB U.S. generics bid as India-linked M&A; heats up

India's Cipla and Lupin made first-round bids for the U.S. generics business of Belgium's UCB, Kremers Urban Pharmaceuticals, according to sources cited by Bloomberg, showing that domestic players are eagerly looking abroad to boost sales.

UCB reportedly gets bids for Kremers Urban unit from Cipla and Lupin

After having to call off a $1.5 billion deal last year to sell its U.S.-based generics business, Belgium's UCB has new bidders for the unit that reportedly includes India's Cipla and Lupin.

Sources: Cipla, Lupin bid on UCB's Kremers Urban

Belgium's UCB has a generics operation in the U.S. with a 400,000-square-foot-manufacturing facility that it has been trying since last year to unload, and India's Cipla and Lupin are both reportedly in the running to buy it.

Serum Institute, Cipla partner to market flu vaccine in India

Serum Institute of India and compatriot Cipla have inked a pact to market a flu vaccine.

Cipla pulls levalbuterol on FDA warning; Wockhardt removes other drugs on concerns

Cipla announced a drug recall of its asthma inhalant levalbuterol from the U.S. market following an FDA warning, and Wockhardt withdrew about a dozen drugs on manufacturing concerns at two of its plants in India.